• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 9, 2021

View Archived Issues
DNA repair

Reversible jacket: Lilly finds good fit in $1.25B-plus deal with RNA editor Proqr

Proqr Therapeutics NV sealed a deal for genetic disorders in the liver and nervous system with Eli Lilly and Co., collecting $50 million in the form of an up-front payment ($20 million) and an equity investment ($30 million), with the prospect of about $1.25 billion more if the arrangement hits research, development and commercialization goals. “The milestones are pretty evenly spread out,” said Smital Shah, Proqr’s chief business and financial officer, though details weren’t provided. Read More

Humanigen's lenzilumab meets FDA refusal on emergency use for COVID-19

Initial efforts at Humanigen Inc. to win an FDA emergency use authorization (EUA) for treating hospitalized COVID-19 patients with its monoclonal antibody, lenzilumab, have failed to gain the regulator's buy-in, sending company shares (NASDAQ:HGEN) down 47.3% to $7.97 on Sept. 9 after touching a 52-week low during the session, a reaction part of a volatile arc that has seen shares climb as high as $29.20 during the same time span. Read More
Financial chart

COVID-19 efforts carry infectious disease stocks amid UTI and HBV defeats

If there is one thing that potently illustrates the hope and despair of the COVID-19 pandemic, it is the zigzag of BioWorld’s Infectious Disease Index. Up by nearly 64%, it is towering over both the Nasdaq Biotechnology Index and the Dow Jones Industrial Average, which are up 12.4% and 15.5%, respectively, but it has experienced several downward swings this year as well. Read More

Astrazeneca eyes potential ‘rescue’ asthma inhaler after double phase III success

Astrazeneca plc is eyeing an addition to its respiratory diseases portfolio after a potential first-in-class “rescue” asthma inhaler, PT-027, met its goals in two phase III trials. Read More
DNA-based antibody delivery graphic

Self-made antibodies could address vexing health questions

Monoclonal antibodies are a triumph of modern medicine. They are also too expensive to be a standard therapy in all but the wealthiest countries. “Having 10% or 15% of your population on antibodies is not sustainable even in wealthy countries,” Rachel Liberatore told BioWorld. Liberatore is director of research and development at Renbio Inc., which is testing the intramuscular delivery of antibody-encoding DNA to prevent and treat infections, including SARS-CoV-2 and HIV. Read More
Judge's gavel with US flag

Novel theories of prosecution emerging among US enforcement agencies

The COVID-19 pandemic has exerted a significant effect on enforcement in the U.S., but Ethan Davis of King & Spalding (K&S) said federal prosecutors have made use of several novel approaches to prosecution in the past year. Read More
Computer chip over digital background with China flag

China’s new personal information protection law challenges company access to user data

China’s Personal Information Protection Law (PIPL) will take effect on Nov. 1, 2021, making it harder for tech firms, including health care companies, to access and use consumers’ personal information. The PIPL was officially passed by the National People’s Congress on Aug. 20. Read More

Appointments and advancements for Sept. 9, 2021

New hires and promotions in the biopharma industry, including: Algernon, Apexigen, Aytu, Benevolentai, Berkeley Lights, Biophytis, Giiant, Jcyte, Neoleukin, Nimble, Orchard, Rani. Read More

Financings for Sept. 9, 2021

Biopharmas raising money in public or private financings, including: Calypso, Evommune, Haemalogix, Hemostemix, Iecure, Lexeo, Lycia, Mammoth Biosciences, Mynd, Tyra. Read More

In the clinic for Sept. 9, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Adlai Nortye, Amgen, Applied Therapeutics, Astrazeneca, Avillion, Azurrx, Biohaven, Calypso, Cardiff, Centessa, Clene, Connect, Cortexyme, Cstone, Denali, Dermavant, Edigene, Ensysce, Erasca, Excalibur, Eyegate, Galera, Gannex, Gensight, Hoth, IGC, Innovent, Inventiva, Isa, Ixaka, Jasper, Kintor, Longboard, Longeveron, Macrogenics, Meiragtx, Metacrine, Novavax, PDS, Resverlogix, Seven and Eight, Sio Gene, Soleno, Stuart, Syros, Telix, Terns, Teva, Wave Life, Xwpharma, Zambon, Zynerba. Read More

Other news to note for Sept. 9, 2021

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Affinia, Agentix, Arctic Vision, Benitec, Biocentriq, BMS, Boehringer, Calcimedica, CG Oncology, Clearside, Flamingo, Herantis, Iecure, Ionis, Mindset, Moderna, Nabriva, Nanoform, Neumentum, Precision, Prevail Infoworks, Rhythm, Sen Jam, Telix, Tevogen, Twist, Venturis. Read More

Regulatory actions for Sept. 9, 2021

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aim Immunotech, Albireo, Ascendis, Azurrx, Benitec, Biocryst, Boehringer, Clover, Decibel, Eli Lilly, Eloxx, Freeline, GNT, Hibercell, Humanigen, Inflarx, Myovant, Nabriva, Pfizer, Phathom, Sigilon, Sinovac, Sinovant, Soin, Soligenix, Tearclear, Viewpoint, Vor. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe